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Abstract
Background: There is a pressing need for high-affinity protein binding ligands for all proteins in the human and other
proteomes. Numerous groups are working to develop protein binding ligands but most approaches develop ligands using
the same strategy in which a large library of structured ligands is screened against a protein target to identify a high-affinity
ligand for the target. While this methodology generates high-affinity ligands for the target, it is generally an iterative
process that can be difficult to adapt for the generation of ligands for large numbers of proteins.
Methodology/Principal Findings: We have developed a class of peptide-based protein ligands, called synbodies, which
allow this process to be run backwards – i.e. make a synbody and then screen it against a library of proteins to discover the
target. By screening a synbody against an array of 8,000 human proteins, we can identify which protein in the library binds
the synbody with high affinity. We used this method to develop a high-affinity synbody that specifically binds AKT1 with a
Kd,5 nM. It was found that the peptides that compose the synbody bind AKT1 with low micromolar affinity, implying that
the affinity and specificity is a product of the bivalent interaction of the synbody with AKT1. We developed a synbody for
another protein, ABL1 using the same method.
Conclusions/Significance: This method delivered a high-affinity ligand for a target protein in a single discovery step. This is
in contrast to other techniques that require subsequent rounds of mutational improvement to yield nanomolar ligands. As
this technique is easily scalable, we believe that it could be possible to develop ligands to all the proteins in any proteome
using this approach.
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Introduction
For the proteomic revolution to be as comprehensive as the
genomic revolution, a large number of protein binding ligands, at
least one for each protein, are needed to specifically detect low
concentrations of a single protein in the presence of a complex
background of proteins, peptides, and lipids [1]. Antibodies are the
most widely used ligand, but can be expensive to produce with
limited control of the production time or the binding properties for
the target protein. These factors have limited the availability of
antibodies for large-scale proteomics applications and have
motivated numerous efforts to develop antibodies and non-
antibody based protein-binding reagents [1,2,3,4,5,6].
Current systems to produce non-antibody protein-binding
reagents use in vitro methods, such as phage and mRNA display,
or SELEX to generate high-affinity ligands to one target protein at
a time (Figure 1A) [7,8,9,10,11,12]. These methods have been
very successful in generating affinity reagents by searching large
libraries of oligonucleotides, small protein domains, or small
peptides, to identify a few reagents with high affinity for the target.
However, these are linear methods that can consume large
quantities of target protein and can take a significant amount of
time due to their iterative nature. It has been noted by the head of
the Human Protein Atlas, that no existing system offers the
potential for high-throughput (HTP) ligand production [13].
Our solution to the affinity reagent problem is to develop a new
class of affinity reagents that can be developed in a high-throughput
manner using minimal amounts of protein. These reagents should
perform like an antibody yet not be subject to some of the limitations
imposed by biological production systems, namely lack of epitope
control, long development time and high cost of production.
Additionally, the reagent should be chemically synthesized so that a
stable supply of reagent can be produced at a reasonable cost. With
these requirements in mind, we devised a new protein binding ligand
called a synthetic antibody or synbody that is composed of two
peptides linked by a scaffold to create a high-affinity binding agent
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10728(Figure 1B). We chose to use long, unstructured peptides, 20 amino
acids (aa) in length, as previous work has shown that these peptides
provide better binding specificity [14]. Two peptides that have low
affinity for a target protein are then linked together to improve the
binding affinity of the construct, a well-known technique to create
high affinity ligands from two low affinity ligands [15,16,17,18,19].
Finally, an orthogonal functional group is used in the linker to allow
the synbody to be coupled to reporter molecules, solid-supports, or to
other proteins.
Although synbodies can be readily produced in a linear fashion
starting with a specific protein target [20], the process, like
producing antibodies, is not high-throughput. In searching for a
method to design a high-throughput ligand generation system, we
wondered if it were possible to build a synbody and then screen it
against a library of proteins to discover its target – in essence by
making ligands backwards (Figure 1C). This idea was built on the
hypothesis that a long (.15 aa), linear peptide has a high
probability of binding, Ppep1, at least weakly to a surface on one or
more proteins in a proteome. By linking together two linear
peptides to create a synbody, the probability that a synbody would
bind a protein, PSyn, would be less than or equal to the product of
the probabilities of binding of each peptide, assuming each peptide
binds an independent site on the target protein.
PsynƒPpep1   Ppep2
If this probability was high and a large library of proteins were
sampled, NSampled, then it is should be possible to screen a single
synbody and discover a number of protein targets, NExpected, for
that synbody.
NExpected~PSyn   NSampled
The availability of arrays of large number of proteins makes this
concept testable and the system potentially high-throughput.
Results and Discussion
To test this approach, a candidate synbody was constructed
using two peptides, AHKVVPQRQIRHAYNRYGSG and
FRGWAHIFFGPHVIYRGGSG, referred to as peptides 1 and
2, respectively. The sequences of the first 17 aa of these peptides
were generated using a random number generator and three
constant positions on the C-terminus that served as a spacer
between the linker scaffold and the active portion of each peptide.
A divergent synthetic method was used in which peptide 1 was
synthesized from C to N terminus from the a-amine of lysine and
peptide 2 was synthesized from the e-amine of lysine (Figure 2A,
Materials and Methods S1, Figure S1). The synbody was tagged
on the C-terminus with biotin and screened against a Life
Technologies ProtoArray
TM. ProtoArrays are nitrocellulose coated
slides onto which 8,303 recombinant human proteins have been
spotted. After a 2-hour incubation, the array was washed and
bound synbody was detected using fluorescently labeled strepta-
vidin. The synbody bound few proteins on the array as seen in the
distribution plot of the top 50 background-subtracted spots
(Figure 2B). Analysis of the brightest spots revealed that the
synbody bound several different proteins including PCCA,
CASZ1, GRP58, NOB1, and AKT1 (Figure 2C). It should be
noted that AKT1, FBXO21, PDE7B, and FBXO4 have multiple
variants (full-length, partial length, or transcript variants) present
on the array, hence the appearance of the protein kinase, RAC-
alpha serine/threonine protein kinase (AKT1) twice in the top 10
proteins bound by the synbody. It is likely that some of the proteins
bound might be false positives as binding levels on protein arrays
can be highly variable, thought to be caused by partial to complete
denaturation of the immobilized protein that arises from protein
printing and array storage [21]. We choose two proteins, AKT1
and protein disulfide-isomerase A3 (GRP58), for further analysis as
recombinant proteins are commercially available.
The synbody (100nM concentration) was screened by Surface
Plasmon Resonance (SPR) against immobilized AKT1 and
Figure 1. Ligand discovery by iterative selection or by backwards selection. (A) Traditional in vitro ligand discovery. (B) Illustration of a
synbody binding to a model protein. Peptide A (gray) and peptide B (red) are synthesized on a peptidic scaffold (blue) that contains an orthogonal
functional group (black) that can be used for conjugation to fluorescent dyes, affinity tags, or solid supports. (C) Ligand discovery by screening a
single ligand against a panel of proteins.
doi:10.1371/journal.pone.0010728.g001
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high affinity for AKT1 and low affinity for GRP58 (Figure S2). To
accurately determine the binding kinetics of the synbody-AKT1
complex, several concentrations of synbody were injected over a
low-density surface of biotin-labeled AKT1 captured on a
Neutratvidin SPR chip using a Biacore A-100. The synbody
bound AKT1 and the resulting sensorgram was fit with a 1:1
binding model to reveal that the synbody had a rapid association
rate, ka=2.0610
5 M
21*sec
21 and a slow dissociation rate,
kd=3.0610
24 sec
21 for a dissociation constant, Kd=1.5 nM
(Figure 3A). A residual plot was constructed from the difference
between the measured sensorgram and the 1:1 fit of the data at
each point in time and the residuals were randomly distributed
around zero, which indicated that the 1:1 binding model was an
appropriate model. The synbody’s binding affinity is in the same
range as that of a monoclonal antibody binding its cognate antigen
[22,23] but was achieved in a single screening step with no further
evolution to achieve nanomolar binding affinity.
The synbody was tested for its ability to bind native protein in
solution. A variant of the synbody was prepared in which the C-
terminal Cys was replaced with a Lys-Biotin. The synbody was
used in an immunoprecipitation (IP) experiment in which it was
bound to streptavidin magnetic beads and incubated overnight
with 89 nM to 0.7 nM solutions of AKT1. The beads were
washed extensively and the bound protein was eluted. Samples
were run on a SDS-PAGE gel and detected by Western Blot with
an anti-AKT1 monoclonal antibody (Figure 3B). As can be seen,
the synbody bound AKT1 from solution.
In order to validate the Kd determined by SPR, an additional IP
was performed using
35S-labeled AKT1 produced by in vitro
translation (IVT). The translation mixture contained 12 mgo f
AKT1 in the presence of 400 mg of total protein and a
concentration series of
35S-labeled AKT1 from 41.5 nM to
80 pM was prepared by dilution of the 35-S-labeled AKT1 IVT
mixture. The synbody was then used to precipitate the
35S-labeled
AKT1 in the same manner as before. Bound AKT1 was
quantified using liquid scintillation counting and plotted as a
function of AKT1 concentration. The resulting isotherm was fit to
a 1:1 binding model using GraphPad Prism and showed the
synbody had a Kd of 4.961.1 nM, in agreement with the SPR
results (Figure 3C). It should be noted that this experiment was
performed in the presence of a cell lysate in which AKT1 was
approximately 3% of the total protein in solution, indicating that
the synbody specifically binds AKT1 from a complex background.
As a preliminary test of specificity, 200 ng of AKT1 (33.2 nM)
was spiked into increasing amounts of cell lysate prepared from
un-stimulated A549 lung epithelial cells and streptavidin beads
coated with 25 pmols of synbody (7.6:1 synbody-to-AKT1 ratio)
were used to pull down AKT1 using the same IP procedure and
Western Blot protocol as before. As can be seen in Figure 3D, the
synbody successfully pulled AKT1 out of the cell lysate in the
presence of an increasing concentration of A549 lysate with little
reduction in AKT1 signal intensity. This result indicates that the
synbody has sufficient affinity and specificity for AKT1 to
precipitate it in the presence of 2,500 fold excess cell extract.
Note that in lane 6 at higher A549 lysate concentration, the
synbody precipitates the very low level endogenous AKT1 from
the un-stimulated cell lysate. This result was confirmed in lane 8
where the synbody was used to precipitate AKT1 from the un-
stimulated A549 lysate when no recombinant AKT1 was present.
However, to more rigorously test the specificity of the synbody,
we reduced the molar ratio of synbody to protein to approximately
2 to 1 and performed an IP to examine other proteins that were
non-specifically bound by the synbody. In this experiment, 400 ng
of AKT1 (66.4 nM) was spiked into 100 and 500 mg of A549 cell
lysate pre-cleared on streptavidin beads (Figure S3) and precip-
itated using streptavidin beads coated with 15 pmols of synbody.
Synbody coated beads and uncoated streptavidin beads were
incubated overnight, washed, and bound proteins were eluted.
Elution samples were split with half of the sample analyzed by
Figure 2. Synbody binding to proteins on protein array. (A) Synbody construct screened against 8,000 protein array. (B) Scatter plot of
synbody binding to top 50 proteins on protein array. (C) Relative fluorescence observed for the top 10 proteins bound by the synbody.
doi:10.1371/journal.pone.0010728.g002
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the silver stained gel, it can be seen AKT1 was precipitated along
with two other prominent proteins from the 500 mg (5mg/ml)
sample. This result indicates the synbody has useful, though not
perfect specificity.
When the synbody was screened on the ProtoArray, it showed little
binding to AKT2, or AKT3 on the array, which share 92% and 87%
sequence identity with AKT1, respectively. This apparent specificity
was investigated further by performing an IP using 250 ng of each
isoform of AKT spiked into 500 mg of A-549 cell lysate. As can be
seen in Figure 3F, the synbody selectively precipitates AKT1 while
precipitating relatively little AKT2 or AKT3, which suggests that the
synbody makes unique contacts on AKT1 that are not present on
either AKT2 or AKT3. This result is in contrast to an anti-AKT1
monoclonal antibody that recognized all three AKT variants on the
protein array (Figure S4).
The simplicity in creating this high affinity ligand to AKT1 was
based on the hypothesis that each unstructured peptide bound a
different site on AKT1 and that the synbody affinity was driven by
the product of the two peptide’s affinity [16,17,18,19,20]. However,it
is possible that the high-affinity binding of just one of the peptides
drives the synbody affinity. To test if the binding was driven by a
single peptide, we used SPR to screen the individual peptides that
made up each arm of the synbody against immobilized AKT1. Each
peptide was synthesized on an automated peptide synthesizer and
purified to .95% purity by HPLC with confirmation by MALDI-
TOF-MS. Each peptide was analyzed by SPR against immobilized
AKT1 and the individual peptides bound AKT1 with micromolar
Figure 3. Characterization of synbody binding to AKT1. (A) SPR sesnorgrams from 12.5 and 6.25 nM solutions of synbody injected over AKT1.
Kinetic fit ofthedatausing a 1:1 binding model is shownin red. (B)I Po fA K T 1us i n gth esy nb o d y .( C) Plot of the amount of
35S-labeledAKT1precipitatedby
the synbody. A fit of the data with a 1:1 binding model is shown in black. (D) Western Blot detection of 200 ng of AKT1 precipitated in the presence of
increasing amounts of A549 cell lysate. Lane 1 is the negative control that shows the amount of AKT1 bound to the streptavidin coated beads from the
200 ng solution of AKT1 in PBS. Lane 8 is the AKT1 control that shows the Western Blot signal from 200 ng of AKT1. (E) Silver stain of proteins precipitated
by synbody from solutionsthat contained 400 ng AKT1 spiked into either 100 or 500 mg of pre-cleared A549 cell lysate. TheWestern Blot confirms that the
dominant band precipitated by the synbody was AKT1. (F) Western Blot detection from IP of 250 ng of AKT1, AKT2, and AKT3 spiked into 500 mg of A549
cell lysate. The same detection antibody was used for AKT1, AKT2, and AKT3 as it recognized all three forms of AKT.
doi:10.1371/journal.pone.0010728.g003
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Figure S5 and are indicative of a low affinity interaction between the
peptides and AKT1. These data imply that the high affinity exhibited
by the synbody is not simply driven by a single high affinity peptide
but could be the consequence of a bivalent interaction between each
peptide and AKT1.
As an orthogonal assessment of whether the peptides bind different
sites on AKT1, each peptide was crosslinked to AKT1 in vitro using a
commercially available set of deuterated / non-deuterated cross-
linkers (BS
3-(d0/d4)). The crosslinkers chemically conjugate primary
amines that are in close proximity to one another (11.4 A ˚)a n dt h e
crosslinked complex is then subjected to enzymatic digestion and
analysis by mass spectrometry. Crosslinked peptides are identified by
the presence of a pair of ions that are separated by 4 mass units
indicating crosslinking with both non-deuterated and deuterated
crosslinkers. Peptide 1 has two possible crosslinking sites (N-terminus
and K at position 3) and peptide 2 has one possible crosslinking site at
the N-terminus. A 10 mM solution of each peptide was added to
2.5 mM AKT1 and incubated for 1 hour prior to the addition of a
100 mM solution of a 1:1 mixture of crosslinkers. After crosslinking,
the mixture was digested with trypsin and analyzed by MALDI-
TOF-MS. It was found that peptide 1 crosslinked to a region of
AKT1 that spans the Protein Kinase (PK) and AGC Kinase domain
w h i l ep e p t i d e2c r o s s l i n k e dt om u l t i p l er e g i o n so nA K T 1( F i g u r e4 A ,
Figure 4B, Table S1), with the majority of crosslinking occurring in
the PK domain, in the region of the ATP binding site (residue 179)
andtheactive site(residue 274).Thelocation ofeachAKT1 fragment
was mapped onto a crystal structure of residues 139–480 of AKT1
(PDB #3CQU) (Figure 4C). As amine reactive cross-linkers will only
react with the side chains of surface exposed lysines, we analyzed the
identified AKT1 fragmentsfor surfaceexposed lysinesand found that
each peptide had 1 exposed lysine. Peptide 1 most likely cross-linked
to
419Lys given that the side chain is exposed while peptide 2 likely
cross-linked to
182Lys,
276Lys, and
481Lys.
The relative intensity data for each peptide 2-AKT1 fragment
and the close proximity of
182Lys and
276Lys, suggests that the
primary binding site for peptide 2 is likely on the PK domain and
that a secondary binding site lies on the AGC domain. The
locations of the cross-linked lysines indicate that it is possible for
the N-terminal region of each peptide to bind AKT1 when linked
as a bivalent synbody. These data and the micromolar binding
affinity of the individual peptides suggest that the high-affinity and
high specificity of the synbody is the product of a bivalent
interaction. Additionally, as the binding site of peptide 1 is in a
region of low homology between AKT1, AKT2, and AKT3
(Figure S6), the selectivity for AKT1 is likely a product of a
bivalent interaction.
To test if this method to produce synbodies backwards is
generally applicable and amenable to HTP parallel processing, 8
other synbodies were synthesized and screened on Proto-
Arrays (Materials and Methods S1, Figure S7, Figure S8, Figure
S9, Table S2). Additionally, we screened 4 monoclonal
antibodies to compare the synbody binding profiles to those of
high-affinity antibodies. A heat map was constructed from the
median normalized fluorescent data and in each case the
synbody produced a unique binding profile suggesting that
each synbody behaves as a unique binding entity (Figure 5A).
Each synbody bound several proteins. It should be noted that
monoclonal antibodies often bind several proteins when screened
on protein arrays [24,25], as was the case for the 4 monoclonal
antibodies that we screened.
From the heat map, some proteins, such as the proto-oncogene
tyrosine kinase ABL1, appeared to bind to multiple synbodies
(Figure 5B). We performed an additional screen of 5 synbodies
that bound ABL1 on the protein array plus 2 negative control
synbodies that were not run on the ProtoArray to test if the
backwards method could be used to identify a functional synbody
to ABL1. We purchased recombinant full-length ABL1 and used
the same IP protocol as before to precipitate 1mg of ABL1
(,700 ng of full-length ABL1 for a concentration of ,54 nM) in a
phosphate buffered saline solution. The silver stained gel showed
that only synbody 9 pulled down ABL1 (Figure 5C). Subsequent
IP assays that used a concentration gradient of ABL1 demon-
strated that synbody 9 had high affinity for ABL1, Kd=12nM
(Figure 5D). We tested the specificity of synbody 9 for ABL1 in a
pull-down assay in which 800 ng of ABL1 (though by western blot
only a small portion of this was full-length protein) was spiked into
100 or 500 mg of pre-cleared A549 lysate (1 mg/mL and 5 mg/
mL protein concentration) and precipitated with synbody 9.
Fifteen pmols of biotinylated synbody 9 was captured on
streptavidin coated beads (,3:1 synbody-to-ABL1 ratio) and the
proteins precipitated by the synbody were analyzed by silver stain
and Western Blot (Figure S10). The synbody precipitated full-
length ABL1 in the presence of .150 and .850 fold excess
protein. Note that the synbody only appears to bind full-length
protein. The Western blot indicates the synbody also precipitated
one other prominent protein from the extract. These results
demonstrate that a high-affinity, moderate specificity synbody can
be readily generated to another protein using this procedure.
Generating ligands to the human and other proteomes is a
major challenge. The unique features of synbodies in combination
with protein arrays may offer a solution. Synbodies are synthesized
by standard peptide chemistry, enabling a large number of them to
be produced in parallel. The ligand screening step is rapid and can
be run in parallel, but the major cost in this system as
demonstrated is the protein arrays. This limitation could be
overcome by multiplexing the synbodies on each array or using
other protein array technologies [21,26,27]. It should be noted
that these synbodies were generated against native protein. While
we have found that they do function in Western blots, synbodies
optimized for functioning in Western blots could be isolated in
screens against denatured proteins.
The two initial synbodies discovered by this method demon-
strated binding affinities in the range of antibodies with specificities
approaching those of commercial antibodies. These synbodies
have low sequence diversity, as synbody 9 and synbody 1 share the
same stretch of 20 amino acids; yet have completely different
protein targets. This echoes recent work that has shown that low
complexity ligand libraries that are highly biased for Tyr and Ser
can be used to produce high affinity and high specificity ligands for
a variety of protein targets [28,29,30]. By incorporating these
findings into an improved design of the peptides that make up the
synbody, it should be possible to improve the binding affinity and
binding specificity. Additionally, we are developing an affinity
optimization method for the peptide arms of the synbody (M.
Greving, N. Woodbury, P.E.B, C.W.D and S.A.J., unpublished
results) that could also be used to improve affinity and specificity.
With these improvements to the first generation of synbodies, we
believe that the backward process of ligand generation could offer
the possibility of creating binding agents to the human proteome.
Materials and Methods
Reagents and materials
Recombinant human AKT1 was purchased from Life Tech-
nologies (Carlsbad, CA, USA) while GRP58 was purchased from
Abnova (Taiwan). Recombinant AKT2 and AKT3 were pur-
chased from Millipore (Milford, MA, USA). Recombinant ABL1
Ligand Discovery - Backwards
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manufacturer. ABL1 concentrations are adjusted to reflect this.
The anti-ABL1 polyclonal antibody was purchased from Abcam
(Cambridge, MA, USA). Monoclonal antibodies for transferrin
(TRF) were purchased from Abcam. The anti-AKT1 antibody was
purchased from Millipore and cross-reacts with AKT2 and AKT3.
The anti-PECAM1 monoclonal antibody was supplied as a gift
from Life Technologies (Carlsbad, CA, USA).
Synbody synthesis
Synbodies were synthesized using two different approaches: i)
multiple antigenic peptide (MAP) [31] constructs were synthesized
using a modified divergent Fmoc solid phase synthesis using
orthogonal protecting groups on branched lysine; ii) linear
synbodies were synthesized using target peptides that were
modified with either an azido or alkyne group and linked using
a Click reaction [32] to either (Pro-Gly-Pro) [33] or (Pro-Pro-Pro)6
[34] scaffold. Details of each synthetic approach are described in
Materials and Methods S1.
All reagents and solvents were analytical, HPLC or peptide
synthesis grade. Commercial reagents and solvents were obtained
from Aldrich and Fisher respectively and used without further
purification unless otherwise noted. All amino acids and resins
were purchased from Novabiochem, Chem Impex International
Inc. as well as from Advanced Chem Tech and used without
further purification. All peptides were synthesized via standard
Fmoc stepwise solid phase peptide synthesis (SPPS) on a
Symphony Multiple Peptide Synthesizer at 25umole scale.
Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF/MS) was carried out on a Bruker
Microflex. UV measurements were carried out on a ND-1000
spectrophotometer instrument. All reversed-phase HPLC analysis
and purifications were conducted on an Agilent 1200. Phenom-
enex Luna 5u analytical (4.66250 mm) and semi-preparative
(106250 mm) C-18 columns were used for the analysis and
purification.
Protein Array experiments
Synbodies were screened on an Invitrogen ProtoArray
TM (Life
Technologies, Carlsbad, CA, USA) detected with Alexa-555
labeled streptavidin (Life Technologies), and scanned using a
Perkin Elmer ProScan Array HTP. The spots were analyzed using
GenePix Pro (Molecular Devices, Sunnyvale, CA, USA) and data
were processed using Genespring GX (Agilent Technologies,
Santa Clara, CA, USA). Synbodies were labeled with biotin using
either Maleimide-PEG2-Biotin (Thermo Pierce, Rockford, IL,
USA) to label the C-terminal cysteine or biotin was incorporated
during synbody synthesis by replacing the C-terminal cysteine with
Lys-biotin (Novabiochem, San Diego, CA, USA). Synbodies were
screened on the array using the recommended protocol with the
following modifications: the arrays were blocked with 5 mL
blocking buffer (50mM HEPES pH 7.5, 200 mM NaCl, 0.08%
Triton X-100, 25% Glycerol, 20mM reduced Glutathione,
1.0mM DTT, 1% BSA) for 90 min. A 200 nM synbody solution
was incubated in probing buffer (16PBS, 1% BSA, 0.1% Tween)
for 90 minutes. Slides were dried by centrifugation at 200g for
1 minute and scanned at 100% laser power and 70% photo-
multiplier voltage. The gal file was obtained for each array by
Figure 4. The two component peptides of bind different sites on AKT1. (A) Sequence of AKT1 illustrating three different domains and the
peptides that were identified by crosslinking. Peptides that crosslinked to peptide 1 are indicated by the black underline while those crosslinked to
peptide 2 are underlined in green. (B) Bar chart of mass spectral intensity (counts) of each cross-linked peptide. Black bars correspond to fragments
crosslinked to peptide 1 and green bars to fragments crosslinked to peptide 2. (C) Location of surface exposed lysine’s from each crosslinked
fragment mapped onto the crystal structure of residues 139–480 of AKT1 (PDB# - 3CQU).
doi:10.1371/journal.pone.0010728.g004
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protoarray.
Data Analysis
Heat maps were constructed using median-normalized data
from each ProtoArray. All responses from the Protoarray were
included except for spots flagged ‘‘poor’’ in GenePix. This includes
spots that failed Invitrogen’s recommended quality control
specifications. Hierarchical clustering using Euclidean distance
was performed on synbody 1 data so that other experiments can
be compared directly to a single ProtoArray intensity.
Synbody Screening by SPR
SPR screening of the synbody against AKT1 and GRP58 was
performed on a Biacore T-100 (GE Healthcare, Piscataway, NJ,
USA). The series S sensor chip CM5, amine coupling reagents and
HBS-EP were obtained from GE Healthcare. A standard amine
immobilization protocol was performed at 25uC using NaHCO3
(10mM in 150mM NaCl, pH 4.5) as the immobilization buffer.
The CM-5 dextran chip was activated by a 10 minute injection of
a freshly prepared 1:1 solution of 400 mM 1-ethyl-3-(3-dimethy-
laminopropyl)-carbodimide (EDC): 100 mM N-hydroxysuccimide
(NHS) in water. The NHS-carboxy groups of the dextran surface
Figure 5. Discovery and characterization of a synbody to ABL1. (A) Heat map of median-normalized fluorescence of 9 synbodies and 4
monoclonal antibodies binding to 8,000 proteins from protein array. Each protein on the array is displayed on the x-axis and the binding intensity is
indicated by color with red corresponding to high intensity and blue corresponding to no binding. Intensities range from 0.01 (blue) to 35 (red)
across all experiments, with yellow indicating intermediate intensity. (B) Background subtracted fluorescence of 9 synbodies and monoclonal
antibodies binding to ABL1. (C) IP screen of ABL1 synbody candidates against a 54 nM solution of ABL1 in PBST. (D) Binding isotherm of the amount
of ABL1 precipitated by synbody 9. A fit of the data with a 1:1 binding model is shown in black.
doi:10.1371/journal.pone.0010728.g005
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sodium acetate (pH 5.0) for 8 mins at a flow rate of 10 ml/min.
Any residual active sites were then quenched by a 5 min pulse of
ethylene diamine (1M, pH 8.5). A 100 nM solution of the synbody
was injected at 30 ml/min across each protein for a 90 second
association phase and a 240 second dissociation phase. Data were
processed using the software supplied by Biacore.
Biotinylation of AKT1
To a solution of AKT1 (25mg, 4.16610
210 moles, 1.0 equiv.) in
50mM Na2CO3 in 150mM NaCl, pH 9.0 (200 ml), was added a
solution of NHS-LC-LC-Biotin (Thermo Scientific) (9.4 ml,
8.32610
210 moles, 2.0 equiv.) in DMSO. The reaction was kept
on ice at 0uC with frequent agitation for 2 hours, before the
mixture was transferred to a 10 kDa Millipore Microcon filter and
diluted with HBS-N (200 ml). The excess biotin was removed by
spinning the filter at 12,000 G until the volume on top of the filter
had been reduced to 0.25 the original volume. The retentate was
washed with an additional 200 ml of HBS-N and spun for a further
15 minutes. The filter was then flipped over and the protein
recovered (15 mg, 60%). After filtration, an appropriate volume of
106 HBS-N was added to the sample to increase the HBS-N
concentration to a 16equivalent.
SPR determination of Kd for AKT1 synbody
Determination of the binding kinetics of the synbody on AKT1
was performed on a Biacore A-100. The series S sensor chip
CM5, amine coupling reagents and HBS-EP were obtained from
GE Healthcare. A standard amine immobilization protocol was
performed at 25uC using NaHCO3 (10mM in 150mM NaCl,
pH 4.5) as the immobilization buffer. Spots 1,2 and 3 on each of
the four flow cells of the CM-5 dextran chip were activated by a
10 minute injection of a freshly prepared 1:1 solution of 40 0mM
EDC : 100 mM NHS in water. The NHS-carboxy groups of spot
1 of the dextran surface were treated with a solution of
neutravidin (50 mg/ml) in sodium acetate (pH 5.0) for 8 mins at
a flow rate of 10 ml/min. Any residual active sites were then
quenched by a 5 min pulse of ethylene diamine (1M, pH 8.5).
Similarly neutravidin was coupled to spots 2 and 3 via a 12 and
16 min injection cycle respectively, followed by quenching. An
additionally 7 min injection of ethylene diamine was then pulsed
over spots 1–3 to ensure no activated sites remained. This
immobilization process was then repeated to couple neutravidin
spots 4 and 5.
Prior to capture of the affinity tagged protein, the chip surface
was conditioned with 8–30 second pulses of 10 mM hydrochlo-
ric acid. Biotinylated AKT1 was injected at 10 mL/min until the
desired level of capture was achieved. Two consecutive 30-
second pulses of amino-PEG2- B i o t i n( 1 m Mi nH B S - N )w e r e
used to quench any excess biotin binding capacity of
neutravidin.
For high-resolution kinetics, biotin-tagged AKT1 was captured
in multiple spot densities with Rmax’s ranging from 20–100 RUs.
Synbody samples spanning 25 nM to 0.78 nM in concentration
were injected in a random order at a flow rate of 30 ml/min over
the flow cell surface. Buffer injections identical to the analyte were
included throughout the analysis for the purpose of double
referencing. Association and dissociation were monitored for 3 and
16 min, respectively. The surfaces were regenerated with 1 30-s
injection of pH 2.5 glycine. To determine the kinetic parameters
of the interaction, each data set was double referenced and fit
globally using a 1:1 interaction model using Biacore A100
Evaluation or BiaEvaluation Software.
Production of
35S-labeled AKT1
AKT1 DNA was assembled by ligation of 42-bp oligonucleo-
tides by PCR according to a procedure developed internally
(Borovkov, et al. submitted). The PCR product was cloned into
pEXP5-NT topo expression vector (Life Technologies), purified
using a Qaigen PCR purification kit, and quantified by Nanodrop
spectrophotometer (Thermo Scientific). Approximately 1mg of the
plasmid containing ATK1 gene was used for in vitro translation
(IVT) using the Expressway
TM Mini Cell-Free Expression System
(Life Technologies). The protein synthesis was carried out in the
ProteoMaster incubator following the manufacturers protocols.
After the reaction was complete, it was placed on ice to stop the
reaction. Approximately 5 mL of supernatant was spotted on a
glass fiber filter for TCA precipitation and yield determination.
For imaging, 5 mL of the IVT reaction was loaded on the SDS
acrylamide gel (Bio-Rad Precast Criterion XT 26-well 4%–12%
Bis-Tris). Gel was run at 150V for 55 minutes, stained with
SimplyBlue (Life Technologies) and dried under vacuum.
Radioactive labeled proteins were transferred to a phosphor
screen and visualized on a Typhoon Trio.
Immunoprecipitation experiments
For all IP experiments, either a 1 mM or 250 nM solution of
biotin-conjugated synbody was captured on 20 mL of streptavidin
coated paramagnetic M-280 Dynabeads (Life Technologies)
according to the manufacturers protocol. Synbody coated beads
were washed five times with 1 mL of 100 mM phosphate buffered
saline containing 0.05% Tween-20 (PBST) and incubated
overnight at 4uC with shaking in the desired amount of target
protein in A549 cell lysate. For Kd determination experiments,
serial dilutions of AKT1 or ABL1 were prepared in binding buffer.
After binding, beads were washed five times with 1 mL of PBST
and heated at 70uCi n2 0 mLo f1 6 LDS loading buffer
(Invitrogen) for 10 minutes. The samples were analyzed by SDS-
PAGE gel with Western Blot detection using the appropriate
antibody and imaged on a GE Healthcare Typhoon Trio.
AKT1 Binding Site Mapping
10 mM of peptide 1 and peptide 2 were individually incubated
with 2.5 mM of recombinant AKT1 (produced in house) in PBS
buffer (200 uL total volume) for one hour, after which an
equimolar ratio of BS
3-d0:BS
3-d4 (Thermo Scientific, Rockford,
IL) crosslinker was added for a total crosslinker concentration of
100 mM. The same concentration of crosslinker was added to a
200 mL control sample containing only 2.5 mM AKT1. Cross-
linking was performed for one hour. After crosslinking, free
peptide and crosslinker were removed from the mixture with a
30 kDa spin filter and at the same time the buffer was exchanged
with 100 mM ammonium bicarbonate pH 8.0. Proteomics grade
trypsin (Sigma-Aldrich, St. Louis, MO) was added to all samples at
a ratio of 1:30 (mol:mol) Trypsin:AKT1 and incubated overnight
at 37uC. Digested samples were lyophilized and reconstituted in
5 mL acetonitrile:H2O (1:1) containing 0.1% trifluoroacetic acid
and spotted on a MALDI target plate along with /-cyano-4-
hydroxycinnamic acid MALDI matrix. Mass spectra were
obtained on an Ultraflex-III MALDI TOF-TOF (Bruker, Bill-
erica, MA) and analyzed in FlexAnalysis (Bruker, Billerica, MA).
IP with Silver Stain Detection
Due to the high-level of A549 lysate protein binding to the
magnetic beads used previously, we pre-cleared the cell lysate
prior to IP. This was accomplished by overnight incubation of
1 mL of lysate (,5 mg/mL) with 1 mL of streptavidin beads. The
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experiments. The IP experiments were performed as before with
the exception that 40 mL of synbody coated beads were used and
the beads were washed seven times with PBST prior to elution.
One half of each elution sample was analyzed by SDS-PAGE
followed by staining using a SNAP Silver Stain kit (Thermo Pierce)
while the other half of the sample was analyzed by SDS-PAGE
with Western Blot detection as before.
Supporting Information
Materials and Methods S1 Contains details of synbody
synthesis.
Found at: doi:10.1371/journal.pone.0010728.s001 (0.05 MB
DOC)
Table S1 Table of fragments identified from crosslinking peptide
1 and peptide 2 with AKT1.
Found at: doi:10.1371/journal.pone.0010728.s002 (0.24 MB
PDF)
Table S2 List of synbodies screened on protein arrays and their
amino acid sequence.
Found at: doi:10.1371/journal.pone.0010728.s003 (0.25 MB
PDF)
Figure S1 Synthesis scheme for MAP synbodies.
Found at: doi:10.1371/journal.pone.0010728.s004 (0.22 MB TIF)
Figure S2 SPR sensorgram from injection of 100 nM synbody
over A) immobilized AKT1 and B) immobilized GRP58.
Found at: doi:10.1371/journal.pone.0010728.s005 (0.35 MB TIF)
Figure S3 Silver stain gel of proteins present in A549 cell lysate
that was pre-cleared using streptavidin coated magnetic beads and
in un-cleared A549 cell lysate.
Found at: doi:10.1371/journal.pone.0010728.s006 (2.68 MB TIF)
Figure S4 Top 10 proteins bound by anti-AKT1 monoclonal
antibody on protein array.
Found at: doi:10.1371/journal.pone.0010728.s007 (0.09 MB TIF)
Figure S5 Sensorgrams from A) 1.88 mM, 0.94 mM, and
0.47 mM solutions of peptide 1 flowed over 15,584 RU of
immoblized AKT1 and B) 20 mM, 10 mM, and 1 mM solutions of
peptide 2 over 19,912 RU of immobilized AKT1. Dissociation
constants were not determined due to the high immobilization
levels of AKT1 used.
Found at: doi:10.1371/journal.pone.0010728.s008 (0.95 MB TIF)
Figure S6 ClustalW alignment of AKT1, AKT2, and AKT3
illustrating AKT1 peptides identified in crosslinking experiments.
Found at: doi:10.1371/journal.pone.0010728.s009 (2.68 MB TIF)
Figure S7 Synthesis scheme for azido modification of peptides.
Found at: doi:10.1371/journal.pone.0010728.s010 (0.21 MB TIF)
Figure S8 Synthesis scheme for alkyne modification of peptides.
Found at: doi:10.1371/journal.pone.0010728.s011 (0.13 MB TIF)
Figure S9 Coupling of peptides using CLICK reaction.
Found at: doi:10.1371/journal.pone.0010728.s012 (0.22 MB TIF)
Figure S10 Silver stain of proteins precipitated by synbody 9
from solutions that contained 800 ng ABL1 spiked into either 100
or 500 mg of pre-cleared A549 cell lysate. Western Blot of same
samples using a polyclonal anti-ABL1 antibody confirming the
presence of ABL1.
Found at: doi:10.1371/journal.pone.0010728.s013 (4.93 MB TIF)
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